- Pharmaceutical Products
- Products By Brand Name
- Products By Dosage Form
- Products By Generic Name
- Products By Therapeutic Class
Find a product
Find Generic
Linadus M
Linagliptin
Description:
Linadus M is a combination of Linagliptin & Metformin Hydrochloride, two oral antihyperglycemic drugs with complimentary mechanism of action. Linagliptin is a Dipeptidyl Peptidase-4 (DPP-4) inhibitor and Metformin is a member of the biguanide class.
Linadus M is a combination of Linagliptin & Metformin Hydrochloride, two oral antihyperglycemic drugs with complimentary mechanism of action. Linagliptin is a Dipeptidyl Peptidase-4 (DPP-4) inhibitor and Metformin is a member of the biguanide class.
Indications:
Linadus M is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.
Linadus M is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.
Mode of Action:
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which exerts its action by slowing the inactivation of incretin hormones. lncretin hormone levels are increased in response to a meal. When blood glucose concentrations are normal or elevated, incretin hormones increase insulin synthesis and releases insulin from pancreatic beta cells. Incretin hormones also lowers glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and increases peripheral glucose uptake and utilization.
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which exerts its action by slowing the inactivation of incretin hormones. lncretin hormone levels are increased in response to a meal. When blood glucose concentrations are normal or elevated, incretin hormones increase insulin synthesis and releases insulin from pancreatic beta cells. Incretin hormones also lowers glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and increases peripheral glucose uptake and utilization.
Different Dosages from Linadus M
Other Brands From Same Therapeutic Class
